Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy

TLDR

Photodynamic therapy kills cancer cells by converting tumour oxygen into singlet oxygen, but tumour hypoxia and oxygen consumption during treatment often limit its efficacy. The authors aim to overcome this limitation by developing oxygen‑self‑enriching photodynamic therapy (Oxy‑PDT) that loads a photosensitizer into perfluorocarbon nanodroplets. Oxy‑PDT is achieved by encapsulating the photosensitizer within perfluorocarbon nanodroplets, which serve as oxygen reservoirs and extend singlet‑oxygen lifetime. In vivo studies show that Oxy‑PDT markedly increases singlet‑oxygen production and cytotoxicity, resulting in significant tumour growth inhibition after both direct and intravenous administration, outperforming conventional PDT and indicating promise for clinical enhancement.

Abstract

Photodynamic therapy (PDT) kills cancer cells by converting tumour oxygen into reactive singlet oxygen ((1)O2) using a photosensitizer. However, pre-existing hypoxia in tumours and oxygen consumption during PDT can result in an inadequate oxygen supply, which in turn hampers photodynamic efficacy. Here to overcome this problem, we create oxygen self-enriching photodynamic therapy (Oxy-PDT) by loading a photosensitizer into perfluorocarbon nanodroplets. Because of the higher oxygen capacity and longer (1)O2 lifetime of perfluorocarbon, the photodynamic effect of the loaded photosensitizer is significantly enhanced, as demonstrated by the accelerated generation of (1)O2 and elevated cytotoxicity. Following direct injection into tumours, in vivo studies reveal tumour growth inhibition in the Oxy-PDT-treated mice. In addition, a single-dose intravenous injection of Oxy-PDT into tumour-bearing mice significantly inhibits tumour growth, whereas traditional PDT has no effect. Oxy-PDT may enable the enhancement of existing clinical PDT and future PDT design.